Mirum Pharmaceuticals 

$105.81
37
+$0.02+0.02% Tuesday 19:55

Statistics

Day High
110.11
Day Low
105.51
52W High
108.62
52W Low
41
Volume
1,176,419
Avg. Volume
-
Mkt Cap
6.38B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
Next
-0.49
-0.31
-0.13
0.06
Expected EPS
-0.43829
Actual EPS
N/A

Financials

-4.48%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.04BRevenue
-46.73MNet Income

Analyst Ratings

131.78Average Price Target
The highest estimate is 175.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MIRM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is involved in developing treatments for liver diseases, directly competing with Mirum's focus on rare liver conditions.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals works on RNAi therapeutics for a variety of conditions, including liver diseases, competing in the same therapeutic space as Mirum.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, positioning it as a competitor in the hepatology market.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has a diverse drug portfolio that includes treatments for liver diseases, making it a competitor in the same market as Mirum.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a wide range of pharmaceutical products, including treatments for liver conditions, competing with Mirum Pharmaceuticals.
Novartis
NVS
Mkt Cap279.67B
Novartis AG engages in the research, development, and marketing of healthcare products, including liver disease treatments, which puts it in competition with Mirum.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. offers a variety of healthcare products and services, including treatments for liver diseases, making it a competitor.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca operates in multiple therapeutic areas, including liver diseases, directly competing with Mirum's product offerings.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb has a diverse portfolio in healthcare, including liver disease treatments, positioning it as a competitor to Mirum Pharmaceuticals.

About

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Show more...
CEO
Mr. Christopher Peetz
Employees
334
Country
United States
ISIN
US6047491013

Listings

0 Comments

Share your thoughts

FAQ

What is Mirum Pharmaceuticals stock price today?
The current price of MIRM is $105.81 USD — it has increased by +0.02% in the past 24 hours. Watch Mirum Pharmaceuticals stock price performance more closely on the chart.
What is Mirum Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mirum Pharmaceuticals stocks are traded under the ticker MIRM.
Is Mirum Pharmaceuticals stock price growing?
MIRM stock has risen by +12.32% compared to the previous week, the month change is a +9.94% rise, over the last year Mirum Pharmaceuticals has showed a +158.07% increase.
What is Mirum Pharmaceuticals market cap?
Today Mirum Pharmaceuticals has the market capitalization of 6.38B
When is the next Mirum Pharmaceuticals earnings date?
Mirum Pharmaceuticals is going to release the next earnings report on July 30, 2026.
What is Mirum Pharmaceuticals revenue for the last year?
Mirum Pharmaceuticals revenue for the last year amounts to 1.04B USD.
What is Mirum Pharmaceuticals net income for the last year?
MIRM net income for the last year is -46.73M USD.
How many employees does Mirum Pharmaceuticals have?
As of May 06, 2026, the company has 334 employees.
In which sector is Mirum Pharmaceuticals located?
Mirum Pharmaceuticals operates in the Health & Wellness sector.
When did Mirum Pharmaceuticals complete a stock split?
Mirum Pharmaceuticals has not had any recent stock splits.
Where is Mirum Pharmaceuticals headquartered?
Mirum Pharmaceuticals is headquartered in Foster City, United States.